| $337M | ||
| $259M | ||
| $79M | ||
| $60M | ||
| $58M | ||
| $50M |
Buys | $343,000 | 2 | 12 |
Sells | $1,277,424 | 15 | 88 |
| Gibney Anthony S | See Remarks | 1 | $245,000 | 1 | $7,823 | $237,177 |
| Johnson David Michael | director | 1 | $98,000 | 0 | $0 | $98,000 |
| Elazzouzi Amy | Vice President, Finance | 0 | $0 | 4 | $29,423 | $-29,423 |
| Kilroy Conor | See Remarks | 0 | $0 | 1 | $39,319 | $-39,319 |
| Plavsic Mark | Chief Technology Officer | 0 | $0 | 2 | $89,393 | $-89,393 |
| Hopkins Janet Jill | Chief Medical Officer | 0 | $0 | 2 | $130,302 | $-130,302 |
| Feder Julie B | Chief Financial Officer | 0 | $0 | 1 | $302,361 | $-302,361 |
| de los Pinos Elisabet | See Remarks | 0 | $0 | 4 | $678,803 | $-678,803 |
Aura Biosciences, Inc. operates as a biotechnology company that develops therapies to treat cancer. The company develops virus-like drug conjugates (VDC) technology platform for the treat tumors of high unmet need in ocular and urologic oncology. It develops AU-011, a VDC candidate for the treatment of primary choroidal melanoma. It also develops AU-011 in additional ocular oncology indications, including choroidal metastases. The company was incorporated in 2009 and is headquartered in Cambridge, Massachusetts.
Over the last 12 months, insiders at Aura Biosciences, Inc. have bought $343,000 and sold $1.28M worth of Aura Biosciences, Inc. stock.
On average, over the past 5 years, insiders at Aura Biosciences, Inc. have bought $16.42M and sold $601,732 worth of stock each year.
Highest buying activity among insiders over the last 12 months: Gibney Anthony S (See Remarks) — $245,000. Johnson David Michael (director) — $98,000.
The last purchase of 20,000 shares for transaction amount of $98,000 was made by Johnson David Michael (director) on 2025‑05‑16.
| 2025-05-16 | Sale | Gibney Anthony S | See Remarks | 1,519 0.0026% | $5.15 | $7,823 | +13.42% | |
| 2025-05-16 | Johnson David Michael | director | 20,000 0.0328% | $4.90 | $98,000 | +13.42% | ||
| 2025-05-16 | Gibney Anthony S | See Remarks | 50,000 0.0819% | $4.90 | $245,000 | +13.42% | ||
| 2025-04-16 | Sale | Kilroy Conor | See Remarks | 7,162 0.0142% | $5.49 | $39,319 | +10.83% | |
| 2025-04-16 | Sale | Elazzouzi Amy | Senior Vice President, Finance | 897 0.0018% | $5.49 | $4,925 | +10.83% | |
| 2025-02-18 | Sale | de los Pinos Elisabet | See Remarks | 20,221 0.0395% | $7.75 | $156,796 | -20.71% | |
| 2025-02-18 | Sale | Hopkins Janet Jill | Chief Medical Officer | 2,534 0.0049% | $7.75 | $19,639 | -20.71% | |
| 2025-02-18 | Sale | Plavsic Mark | Chief Technology Officer | 2,151 0.0042% | $7.75 | $16,670 | -20.71% | |
| 2025-02-18 | Sale | Elazzouzi Amy | Senior Vice President, Finance | 1,404 0.0027% | $7.75 | $10,881 | -20.71% | |
| 2025-01-21 | Sale | de los Pinos Elisabet | See Remarks | 15,955 0.0308% | $7.67 | $122,381 | -20.05% | |
| 2025-01-21 | Sale | Elazzouzi Amy | Vice President, Finance | 1,001 0.0019% | $7.67 | $7,679 | -20.05% | |
| 2024-11-18 | Sale | Hopkins Janet Jill | Chief Medical Officer | 11,822 0.0244% | $9.36 | $110,663 | -18.54% | |
| 2024-10-29 | Sale | de los Pinos Elisabet | See Remarks | 9,200 0.0186% | $10.74 | $98,788 | -29.97% | |
| 2024-10-29 | Sale | Elazzouzi Amy | Vice President, Finance | 553 0.0011% | $10.74 | $5,938 | -29.97% | |
| 2024-10-18 | Sale | de los Pinos Elisabet | See Remarks | 24,992 0.0517% | $12.04 | $300,839 | -35.78% | |
| 2024-10-18 | Sale | Feder Julie B | Chief Financial Officer | 25,131 0.0519% | $12.03 | $302,361 | -35.78% | |
| 2024-10-16 | Sale | Plavsic Mark | Chief Technology Officer | 7,383 0.0163% | $9.85 | $72,723 | -26.24% | |
| 2024-01-23 | Sale | de los Pinos Elisabet | See Remarks | 15,853 0.0323% | $7.64 | $121,141 | +7.07% | |
| 2024-01-23 | Sale | Feder Julie B | Chief Financial Officer | 6,609 0.0135% | $7.64 | $50,521 | +7.07% | |
| 2023-11-09 | Matrix Capital Management Company, LP | 10 percent owner | 1.56M 5.251% | $9.00 | $14.04M | +15.24% |
| de los Pinos Elisabet | See Remarks | 482440 0.7781% | $2.94M | 0 | 8 | |
| Hopkins Janet Jill | Chief Medical Officer | 269794 0.4351% | $1.65M | 0 | 2 | |
| Plavsic Mark | Chief Technology Officer | 209456 0.3378% | $1.28M | 0 | 2 | |
| Kilroy Conor | See Remarks | 179313 0.2892% | $1.09M | 0 | 1 | |
| Johnson David Michael | director | 166167 0.268% | $1.01M | 10 | 0 | <0.0001% |
| Feder Julie B | Chief Financial Officer | 134276 0.2166% | $819,083.60 | 0 | 5 | |
| Elazzouzi Amy | Senior Vice President, Finance | 81381 0.1313% | $496,424.10 | 0 | 4 | |
| Gibney Anthony S | See Remarks | 58452 0.0943% | $356,557.20 | 1 | 1 | |
| Matrix Capital Management Company, LP | 10 percent owner | 6922870 11.1651% | $42.23M | 3 | 0 | <0.0001% |
| Medicxi Ventures Management (Jersey) Ltd | director | 2969352 4.7889% | $18.11M | 1 | 0 | <0.0001% |
| Rich Cadmus | See Remarks | 24578 0.0396% | $149,925.80 | 0 | 1 | |
| De Rosch Mark | Chief Operating Officer | 16385 0.0264% | $99,948.50 | 0 | 1 |
$21,797,027 | 94 | 5.08% | $348.06M | |
$587,109,125 | 90 | 3.17% | $439.82M | |
$14,527,743 | 76 | 38.40% | $357.77M | |
$56,593,094 | 24 | 46.48% | $349.35M | |
$24,857,912 | 21 | -35.40% | $467.75M | |
$26,923,982 | 20 | -17.22% | $396.6M | |
$3,287,638 | 15 | -0.23% | $367.4M | |
$46,442,839 | 15 | -20.05% | $366.08M | |
$70,704,995 | 14 | 67.19% | $369.64M | |
$7,254,955 | 14 | 20.70% | $346.01M | |
Aura Biosciences, Inc. (AURA) | $65,355,913 | 13 | -3.42% | $378.23M |
$81,667,942 | 12 | -57.54% | $350.79M | |
$3,073,199 | 10 | 16.77% | $447.2M | |
$157,484,277 | 8 | 28.67% | $382.74M | |
$49,529,960 | 6 | 32.16% | $454.62M | |
$79,246,559 | 5 | -27.73% | $360.45M | |
$8 | 2 | 28.83% | $392.18M | |
$3,850,000 | 1 | -51.32% | $429.87M | |
$3,250,000 | 1 | -44.91% | $432.34M |
| Increased Positions | 46 | +43.4% | 5M | +13.79% |
| Decreased Positions | 43 | -40.57% | 5M | -12.56% |
| New Positions | 16 | New | 4M | New |
| Sold Out Positions | 15 | Sold Out | 5M | Sold Out |
| Total Postitions | 109 | +2.83% | 40M | +1.23% |
| Matrix Capital Management Company, Lp | $42,576.00 | 13.85% | 6.92M | 0 | 0% | 2024-12-31 |
| Adage Capital Partners Gp, L.L.C. | $30,019.00 | 9.76% | 4.88M | 0 | 0% | 2024-12-31 |
| Eventide Asset Management, Llc | $25,096.00 | 8.16% | 4.08M | -2M | -29.68% | 2024-12-31 |
| Blackrock, Inc. | $21,771.00 | 7.08% | 3.54M | -11,509 | -0.32% | 2025-03-31 |
| Medicxi Ventures Management (Jersey) Ltd | $18,695.00 | 6.08% | 3.04M | 0 | 0% | 2025-03-31 |
| Long Focus Capital Management, Llc | $15,607.00 | 5.08% | 2.54M | +1M | +123.88% | 2024-12-31 |
| Vanguard Group Inc | $11,794.00 | 3.84% | 1.92M | +112,296 | +6.22% | 2024-12-31 |
| Franklin Resources Inc | $10,597.00 | 3.45% | 1.72M | +54,103 | +3.24% | 2024-12-31 |
| Nantahala Capital Management, Llc | $7,811.00 | 2.54% | 1.27M | 0 | 0% | 2024-12-31 |
| Levin Capital Strategies, L.P. | $7,673.00 | 2.5% | 1.25M | +833,984 | +201.62% | 2024-12-31 |